Last reviewed · How we verify
Dapagliflozin (Forxiga)
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | Dapagliflozin (Forxiga) |
|---|---|
| Also known as | SGLT-2 inhibitor, Farxiga |
| Sponsor | National Institute of Cardiology, Warsaw, Poland |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
By blocking SGLT2, dapagliflozin prevents the reabsorption of filtered glucose in the proximal tubule of the nephron, leading to increased urinary glucose loss and lower blood glucose levels. Beyond glycemic control, SGLT2 inhibition reduces cardiac preload and afterload, improves myocardial energetics, and has cardioprotective and renoprotective effects independent of glucose lowering.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Hypotension
- Diabetic ketoacidosis
Key clinical trials
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- SGLT2 Inhibition in Hemodialysis (PHASE2)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs (NA)
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction (PHASE3)
- iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) (PHASE3)
- Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (PHASE3)
- Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapagliflozin (Forxiga) CI brief — competitive landscape report
- Dapagliflozin (Forxiga) updates RSS · CI watch RSS
- National Institute of Cardiology, Warsaw, Poland portfolio CI